Skip to main content

Table 1 Select ongoing clinical trials for epidermal growth factor receptor tyrosine kinase inhibitors in the neoadjuvant setting

From: Osimertinib as neoadjuvant therapy in a patient with stage IIIA non-small cell lung cancer: a case report

Study title Conditions Interventions ClinicalTrials.gov identifier
Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations Stage II NSCLC, Stage IIIA NSCLC Erlotinib NCT01470716
Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage IIIA-N2 Non-small Cell Lung Cancer EGFR-positive Non-Small Cell Lung Cancer Icotinib NCT03749213
Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery Stage I NSCLC
Stage IA NSCLC, Stage IB NSCLC, Stage II NSCLC
Stage IIA NSCLC
Stage IIB NSCLC
Stage IIIA NSCLC
Osimertinib NCT03433469
Neoadjuvant Afatinib Therapy for Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma Resectable EGFR positive stage III NSCLC Afatinib NCT04201756
Neoadjuvant Gefitinib followed by Surgery and Gefitinib In Unresectable Stage III NSCLC With EGFR Mutations
(NEGOTIATE)
Unresectable EGFR positive stage III NSCLC Gefitinib NCT02347839
  1. NSCLC non-small cell lung cancer, EGFR epidermal growth factor receptor